Interactive Breakout Discussions

WEDNESDAY, 17 MARCH, 10.15am - 10.45am

FACILITATED, SMALL-GROUP DISCUSSIONS. INTERACTIVE PARTICIPATION LEADS TO PROBLEM-SOLVING SOLUTIONS AND FUTURE COLLABORATIONS AROUND FOCUSED TOPICS.

Join your colleagues and fellow delegates for a focused, informal discussion moderated by a member of our speaking faculty.  A small group format allows participants to meet potential collaborators, share examples from their own work and discuss ideas with peers.
Technologies for the Future of Bioprocess Development: What Are They and How to Choose?
Moritz von Stosch, PhD, Chief Innovation Officer, Datahow, Switzerland
  • What are the bioprocess (development) technologies of the future?​
  • How to focus effort on the most relevant technologies for bioprocess (development) of the future?
  • Will our current business models still work?
  • How do new modalities change the bioprocess (development) landscape?

DSP, Process Intensification and Digitalization

Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences (BOKU)
  • Common DSP challenges
  • Integrated continuous manufacturing
  • Process control
  • Digitalization

Gene Therapy CMC and Manufacturing

Christopher Bravery, PhD, Consulting Regulatory Scientist, Consulting on Advanced Biologicals Ltd.
Florence Salmon, PhD, Independent Consultant, Former, Director Regulatory Affairs CMC, Novartis Pharma AG
  • Common Analytical Challenges for Viral Vectors
  • ​Potency Assay Development
  • Process Development and Scale-up
  • Process Change and Comparability

Optimising Formulation Development for Novel Modalities, High and Low Concentration Protein Formulations, Combination Products and Co-Formulations

Paul Dalby, PhD, Professor, Biochemical Engineering, University College London, United Kingdom
  • Rapid formulation of novel formats, eg. mRNA, viral vectors, exosomes
  • New directions with established modalities, eg. mAbs
  • Analytical advances and challenges
  • How to handle the very low concentration products

 

 

 

Register